Abbott Laboratories (SIX: ABT.SW) Stock Competitors & Peer Comparison

Abbott Laboratories (SIX: ABT.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT.SW stands at 125.5B. In comparison, ZBH.SW has a market cap of 15B. Regarding current trading prices, ABT.SW is priced at CHF 72.50 on the SIX, while ZBH.SW trades at CHF 77.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT.SW currently has a P/E ratio of 19.79, whereas ZBH.SW's P/E ratio is 12.53. In terms of profitability, ABT.SW's ROE is +0.11%, compared to ZBH.SW's ROE of +0.06%. Regarding short-term risk, ABT.SW is similarly volatile compared to ZBH.SW. This indicates similar risk in terms of short-term price fluctuations for ABT.SW.Check ZBH.SW's competition here

Abbott Laboratories (SIX: ABT.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT.SW stands at 125.5B. In comparison, SOON.SW has a market cap of 14.1B. Regarding current trading prices, ABT.SW is priced at CHF 72.50 on the SIX, while SOON.SW trades at CHF 237.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT.SW currently has a P/E ratio of 19.79, whereas SOON.SW's P/E ratio is 26.04. In terms of profitability, ABT.SW's ROE is +0.11%, compared to SOON.SW's ROE of +0.17%. Regarding short-term risk, ABT.SW is less volatile compared to SOON.SW. This indicates lower risk in terms of short-term price fluctuations for ABT.SW.Check SOON.SW's competition here

Abbott Laboratories (SIX: ABT.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT.SW stands at 125.5B. In comparison, MED.SW has a market cap of 1.1B. Regarding current trading prices, ABT.SW is priced at CHF 72.50 on the SIX, while MED.SW trades at CHF 86.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT.SW currently has a P/E ratio of 19.79, whereas MED.SW's P/E ratio is 72.08. In terms of profitability, ABT.SW's ROE is +0.11%, compared to MED.SW's ROE of +0.05%. Regarding short-term risk, ABT.SW is less volatile compared to MED.SW. This indicates lower risk in terms of short-term price fluctuations for ABT.SW.Check MED.SW's competition here

Abbott Laboratories (SIX: ABT.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT.SW stands at 125.5B. In comparison, METN.SW has a market cap of 387.5M. Regarding current trading prices, ABT.SW is priced at CHF 72.50 on the SIX, while METN.SW trades at CHF 865.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT.SW currently has a P/E ratio of 19.79, whereas METN.SW's P/E ratio is -35.95. In terms of profitability, ABT.SW's ROE is +0.11%, compared to METN.SW's ROE of -0.03%. Regarding short-term risk, ABT.SW is less volatile compared to METN.SW. This indicates lower risk in terms of short-term price fluctuations for ABT.SW.Check METN.SW's competition here